Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy versus radiotherapy plus temozolomide for high-risk low-grade gliomas
ChiCTR1800015199Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in glioma (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: progression-free survival. Started Jun 2018; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR1800015199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015199.